Brendan Technologies Secures Pre-Release Purchase of STATLIA(R) Quantum with Top Ten Pharmaceutical Company.

New Assay Analysis Software Demonstrates Scalability and Flexibility

CARLSBAD, Calif. -- While Brendan Technologies, Inc. (OTCBB: BDTE), an innovative analytical software company, is completing the development of its powerful new assay analysis software, STATLIA[R] Quantum, one of the world's top ten pharmaceutical companies has already made an advance purchase of the system for one of its worldwide locations. Neither the terms of the agreement nor the company's name was disclosed.

Brendan Technologies also has already inked a license agreement for STATLIA Quantum with Invitrogen (NASDAQ:IVGN) to facilitate the analysis of protein samples.

STATLIA Quantum offers "quantum leap" advancement in assay analysis software due to its scalability, flexibility, and industry-leading computational analysis tools. Written in an advanced architectural design on a .NET framework, the new software can be centrally administered throughout an organization by the IT department. It has the flexibility to analyze multiple technologies and applications in the laboratory, along with offering a number of unique analysis tools made possible by its advanced and proprietary computational capabilities.

"This purchase adds to the confirmation that STATLIA Quantum is well positioned in the biopharmaceutical industry to address currently unmet critical needs for assay analysis," said John Dunn, PhD, Chief Executive Officer of Brendan Technologies. "The fact that major industry players are willing to make pre-release purchases of STATLIA Quantum underscores the need for the unique and advanced assay analysis capabilities that this software brings to the drug development process."

One of the industry's leading experts in the field of immunoassay and bioassay testing, Dr. Dunn serves as an IBC Life Sciences instructor teaching comprehensive training courses on the subject of "Analyzing Biological Assays" to the biopharmaceutical industry, and has authored several key papers on the subject. He has been invited by the United States Pharmacopeia (USP) regulatory agency to make a presentation at its annual USP Bioassay Workshop held August 14 on three methods used for drug potency testing. Brendan has incorporated all three methods under discussion in its new STATLIA Quantum software.

About Brendan Technologies, Inc.

Brendan Technologies, a developer and marketer of innovative analytical software, is actively providing software solutions to improve the accuracy, quality control, workflow, and regulatory compliance of immunoassay and bioassay testing in laboratories in the biopharmaceutical, clinical, research, veterinarian and agricultural industries. The Company's customers, many of whom are Fortune 1000 organizations, represent some of the largest corporations in their respective fields. Brendan Technologies is continually redesigning and expanding its product lineup to better capitalize on the growing demand of its target markets for more advanced software.

Background on Immunoassay Testing

Immunoassays are one of the world's largest and fastest growing testing technologies used to diagnose diseases, discover new chemical entities and biological products, provide vital data in the development of drugs in FDA clinical trials, and assist in quality control of drug manufacturing and drug screening. It is also one of the largest technologies used in environmental testing. Currently, $50 billion is spent globally on immunoassay testing, with approximately $1 billion of that being spent on immunoassay software.

Immunoassays are highly sensitive and specific chemical tests used to detect and quantify extremely minute substances in blood, body fluid and other biological samples, using an immunological reaction. These tests measure the formation of antibody-antigen complexes and detect them via an indicator reaction. Their high specificity results from the use of antibodies and purified antigens as reagents. High sensitivity is achieved by using an indicator system that results in amplification of the measured product. Immunoassays may be qualitative (positive or negative) or quantitative (amount measured).

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-KSB, as amended, for the most recently ended fiscal year. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.